Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
The Diagnostic Equipment Service Conundrum How Much Is Too Much? How Little Is Too Little?
In light of laboratory pressures to do more with less, laboratory managers transfer cost control onto vendors by means of a constant push for price reductions. In this commercial climate, efficient management of customer and technical service extras is critical. Expertise in managing service offerings will help companies offer service programs that are just enough to differentiate them from the competition. Service programs that offer too much may result in revenue loss. Programs that are perceived to be inadequate place the company at a competitive disadvantage.
In The Diagnostic Equipment Service Conundrum: How Much is Too Much? How Little is Too Little? Kalorama Information's analyst Shara Rosen provides a unique benchmarking tool not available from any other syndicated source consisting of the instrument-specific service offerings, managed service offerings, and remote diagnostic capabilities and offerings of selected major IVD companies. This research can assist service and product managers developing a service plan, as well as marketing executives interested in the competiveness of company offerings.
Dade Behring
GE Healthcare (Abbott Diagnostics)
Ortho Clinical Diagnostics (OCD), Johnson & Johnson
Roche Diagnostics
Siemens (Bayer and Diagnostic Products Corp. (DPC))
Sysmex
Rosen, the author of Kalorama's best-selling In Vitro Diagnostics: The World Market report analyzes each aspect of service: On-site field service programs, training, technical support, installation and integration and technical bulletins are examined. Specific instuments considered include:
Clinical Chemistry/Integrated Analyzers
Immunoassay Analyzers
Hematology Analyzers
Coagulation Instrumentation
Laboratory Automation
As part of Kalorama Information's analysis, hosptial lab employees and company representatives were contacted. Research of online sources was also conducted, and information was analyzed by an expert with experience in diagnostic service offerings.
Published: Jul 1, 2007
56 Pages
PDF Format
Table of Contents
Price: $2,995.00 / GBP1,497.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.